News

Ecora Resources Reports Pretax Loss in First Half of the Year

1 Mins read

Ecora Resources, a commodities-focused royalty company, has announced that it experienced a significant pretax loss in the first half of the year. The company attributes this loss to a decrease in revenue from royalties and metal-stream-related sources.

Previously known as Anglo Pacific Group, Ecora Resources reported a pretax loss of $10.2 million for the half-year period, contrasting with a profit of $130.0 million in the same period last year.

The decline in revenue can be attributed to lower royalty and metal-stream-related earnings. Additionally, the Queensland-based Kestrel coal mine’s revaluation to account for depletion in the period also contributed to the negative swing.

Ecora Resources’ total portfolio contribution dropped by 52% to $44.5 million, primarily due to reduced royalty income from the Kestrel mine.

Looking ahead, Ecora Resources plans to undergo a multi-year transition phase during which it will shift its focus towards future-oriented commodities such as copper, nickel, lithium, and cobalt. This strategic shift aims to reduce the company’s dependence on revenue from Kestrel.

According to Chief Executive Marc Bishop Lafleche, the long-term outlook for decarbonizing commodities remains highly promising. The favorable market conditions, combined with limited growth capital for mining companies, have increased the opportunities for royalty acquisitions.

Related posts
News

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…
News

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…
News

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *